Science Behind the Numbers, The Business of Health - Research Report on Endo Health Solutions Inc, Actavis Inc, Mylan Inc., Elan Corporation, plc and Amgen, Inc.

NEW YORK, February 28, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Endo Health Solutions Inc (NASDAQ: ENDP), Actavis Inc (NYSE: ACT), Mylan Inc. (NASDAQ: MYL), Elan Corporation, plc (NYSE: ELN) and Amgen, Inc. (NASDAQ: AMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Endo Health Solutions Inc Research Report

Endo Health Solutions gained 7.9 percent after the company named Rajiv De Silva as president and CEO. Rajiv De Silva's experience includes serving as President of Valeant Pharmaceuticals. His turnaround plan for Valeant resulted in significant increases in revenue through acquisitions and organic sales growth. Many believe that under his leadership, Endo is bound for recovery. According to Roger Kimmel, chairman of Endo, Rajiv is a strong leader with deep industry experience and has a track record in generating growth and profitability. A few weeks ago, it was also reported that Endo is exploring talks with drug makers that are potentially interested in acquiring the company. Endo has not issued a statement regarding the potential buyout, but UBS analysts comment that it would not be surprising if global specialist pharmaceutical companies or financial buyers end up bidding for Endo. Endo's largest shareholder, Fidelity Investments, is also pushing the drug maker to consider a sale. Endo is scheduled to report its fourth quarter earnings on Feb. 28. The Full Research Report on Endo Health Solutions Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/49e0_ENDP]

--

Actavis Inc Research Report

Actavis just came from a strong fourth quarter, with net revenue up 29 percent to $5.91 billion. Moreover, Actavis announced that the US Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for Buprenorphine HCI and Naloxone HCI Dihydrate SL Tablet, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone. The drug is for the maintenance of opioid dependence. Many are encouraged by the company's strong pipeline and believe that it is in a position for sustainable long-term growth, especially with few major drugs that have patents that are due to expire in the near future. The Full Research Report on Actavis Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/d9b4_ACT]

--

Mylan Inc. Research Report

Mylan Inc.'s subsidiaries have been actively rolling out new products to customers. First off, Mylan Pharmaceuticals has launched Fenofibrate capsules USP, the generic version of Lupin Atlantis' S.A. Antara capsules. These capsules reduce levels of LDL-C, Total-C, triglycerides, and Apo B and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia. Mylan (Proprietary) Limited also launched a portfolio of antiretroviral (ARV) products, which are affordable and high-quality treatment for HIV/AIDS in South Africa. With 184 ANDAs pending FDA approval representing $80.7 billion in annual sales, many are believe that Mylan is a good bet for long-term growth. The company is set to report its fourth quarter results on Feb 27. On average, analysts expect Mylan to report earnings of 64 cents per share. The Full Research Report on Mylan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/02c5_MYL]

--

Elan Corporation, plc Research Report

Elan Corporation has confirmed that RP Management LLC (Royalty Pharma) has proposed to buy Elan Corp for $6.5 billion. The informal offer of $11 per American depositary receipt is 3.8 percent above Elan's closing price on Feb 22. According to Leerink Swann & Co. analyst Marko Kozul, Royalty Pharma is in "the best candidate for this transaction." According to Elan, it is considering the deal alongside other strategic transactions. Its other transactions include selling its stake in the Tysabri multiple-sclerosis drug to Biogen Inc. The proceeds of this will be used to reinvest in late-stage experimental products or some early-stage clinical research projects. Elan's share rose to $11.14 following the announced proposal and many are eager for the sale of the company. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/294e_ELN]

--

Amgen, Inc. Research Report

Shares for Amgen rose after Affymax Inc's national voluntary recall of all Omontys drugs after reports of serious hypersensitivity reactions. Omontys is used to treat chronic anemia in patients who have chronic kidney disease and are undergoing dialysis. It is the primary competitor to Amgen's core anemia drugs Epogen and Aranesp. According to Oppenheimer analyst Boris Peaker, Epogen, with sales of $1.9 billion in the US, is most likely to benefit from the Omontys recall. Furthermore, UBS analyst Matthew Roden stated that the FDA might become more cautious about the safety of newer anemia drugs and generic versions of biotech drugs following the omontys recall. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/767e_AMGN]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: [email protected]
Main: +1-480-745-7826

SOURCE Investors-Alliance